cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.25071026
title: Supplementary materials: Distinguishing cardiac catheter ablation energy modalities by applying natural language processing to electronic health records

description: <b>These are peer-reviewed supplementary tables for the article '</b><b>Distinguishing cardiac catheter ablation energy modalities by applying natural language processing to electronic health records</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><br><b>Table 1: </b>ICD10 codes for atrial fibrillation<b>Table 2:</b> ICD10 codes for atrial flutter<b>Table 3: </b>Inpatient and outpatient atrial fibrillation ablation procedure codes<b>Table 4:</b> Illustrative screenshot of validation and natural language processing (NLP) table links<b>Table 5:</b> 60-day <i>de novo </i>sensitivity analysis<b>Aim:</b> Catheter ablation is used to treat symptomatic atrial fibrillation (AF) and is performed using either cryoballoon (CB) or radiofrequency (RF) ablation. There is limited real world data of CB and RF in the US as healthcare codes are agnostic of energy modality. An alternative method is to analyze patients’ electronic health records (EHRs) using Optum’s EHR database. <b>Objective:</b> To determine the feasibility of using patients’ EHRs with natural language processing (NLP) to distinguish CB versus RF ablation procedures. <b>Data Source:</b> Optum R ? de-identified EHR dataset, Optum R ? Cardiac Ablation NLP Table. <b>Methods</b>: This was a retrospective analysis of existing de-identified EHR data. Medical codes were used to create an ablation validation table. Frequency analysis was used to assess ablation procedures and their associated note terms. Two cohorts were created (1) index procedures, (2) multiple procedures. Possible note term combinations included (1) cryoablation (2) radiofrequency (3) ablation, or (4) both. <b>Results:</b> Of the 40,810 validated cardiac ablations, 3777 (9%) index ablation procedures had available and matching NLP note terms. Of these, 22% (n = 844) were classified as ablation, 27% (n = 1016) as cryoablation, 49% (n = 1855) as radiofrequency ablation, and 1.6% (n = 62) as both. In the multiple procedures analysis, 5691 (14%) procedures had matching note terms. 24% (n = 1362) were classified as ablation, 27% as cryoablation, 47% as radiofrequency ablation, and 2%as both. <b>Conclusion:</b> NLP has potential to evaluate the frequency of cardiac ablation by type, however, for this to be a reliable real-world data source, mandatory data entry by providers and standardized electronic health reporting must occur.
DOI: 10.6084/m9.figshare.25071026.v1
title: Supplementary materials: Distinguishing cardiac catheter ablation energy modalities by applying natural language processing to electronic health records

description: <b>These are peer-reviewed supplementary tables for the article '</b><b>Distinguishing cardiac catheter ablation energy modalities by applying natural language processing to electronic health records</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><br><b>Table 1: </b>ICD10 codes for atrial fibrillation<b>Table 2:</b> ICD10 codes for atrial flutter<b>Table 3: </b>Inpatient and outpatient atrial fibrillation ablation procedure codes<b>Table 4:</b> Illustrative screenshot of validation and natural language processing (NLP) table links<b>Table 5:</b> 60-day <i>de novo </i>sensitivity analysis<b>Aim:</b> Catheter ablation is used to treat symptomatic atrial fibrillation (AF) and is performed using either cryoballoon (CB) or radiofrequency (RF) ablation. There is limited real world data of CB and RF in the US as healthcare codes are agnostic of energy modality. An alternative method is to analyze patients’ electronic health records (EHRs) using Optum’s EHR database. <b>Objective:</b> To determine the feasibility of using patients’ EHRs with natural language processing (NLP) to distinguish CB versus RF ablation procedures. <b>Data Source:</b> Optum R ? de-identified EHR dataset, Optum R ? Cardiac Ablation NLP Table. <b>Methods</b>: This was a retrospective analysis of existing de-identified EHR data. Medical codes were used to create an ablation validation table. Frequency analysis was used to assess ablation procedures and their associated note terms. Two cohorts were created (1) index procedures, (2) multiple procedures. Possible note term combinations included (1) cryoablation (2) radiofrequency (3) ablation, or (4) both. <b>Results:</b> Of the 40,810 validated cardiac ablations, 3777 (9%) index ablation procedures had available and matching NLP note terms. Of these, 22% (n = 844) were classified as ablation, 27% (n = 1016) as cryoablation, 49% (n = 1855) as radiofrequency ablation, and 1.6% (n = 62) as both. In the multiple procedures analysis, 5691 (14%) procedures had matching note terms. 24% (n = 1362) were classified as ablation, 27% as cryoablation, 47% as radiofrequency ablation, and 2%as both. <b>Conclusion:</b> NLP has potential to evaluate the frequency of cardiac ablation by type, however, for this to be a reliable real-world data source, mandatory data entry by providers and standardized electronic health reporting must occur.
DOI: 10.6084/m9.figshare.25070999
title: Supplementary materials: Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison

description: <b>This is a peer-reviewed supplementary table for the article '</b><b>Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><br><b>Supplementary Table 1: </b>Efficacy outcomes by treatment arm<b>Aim:</b> To compare the efficacy of erenumab versus rimegepant as preventive treatment for patients with episodic and chronic migraine using an anchor-based matching-adjusted indirect comparison. <b>Methods:</b> Patients from two phase II/III trials for erenumab (NCT02066415 and NCT02456740) were pooled and weighted to match on the baseline effect modifiers (age, sex, race, baseline monthly migraine days [MMDs], and history of chronic migraine [CM]) reported in the phase II/III trial for rimegepant (NCT03732638). Four efficacy outcomes were compared between the two erenumab regimens (70 mg and 140 mg) and rimegepant, including changes in MMDs from baseline to month 1 and month 3, changes in Migraine-Specific Quality of Life Questionnaire role function – restrictive domain score from baseline to month 3, and change in disability from baseline to month 3. <b>Results: </b>Compared with rimegepant, erenumab 70 mg was associated with a statistically significant reduction in MMDs at month 3 (-0.90 [-1.76, -0.03]; p = 0.042) and erenumab 140 mg was associated with statistically significant reductions in MMDs at month 1 (-0.94 [-1.70, -0.19]; p = 0.014) and month 3 (-1.28 [-2.17, -0.40]; p = 0.005). The erenumab regimens also had numerical advantages over rimegepant for other efficacy outcomes. <b>Conclusion</b>: In the present study, we found that erenumab had a more favorable efficacy profile than rimegepant in reducing MMDs at month 1 and month 3 for migraine prevention. These results may help with decision-making in clinical practice and can be further validated in future clinical trials or real-world studies.
DOI: 10.6084/m9.figshare.25070999.v1
title: Supplementary materials: Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison

description: <b>This is a peer-reviewed supplementary table for the article '</b><b>Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><br><b>Supplementary Table 1: </b>Efficacy outcomes by treatment arm<b>Aim:</b> To compare the efficacy of erenumab versus rimegepant as preventive treatment for patients with episodic and chronic migraine using an anchor-based matching-adjusted indirect comparison. <b>Methods:</b> Patients from two phase II/III trials for erenumab (NCT02066415 and NCT02456740) were pooled and weighted to match on the baseline effect modifiers (age, sex, race, baseline monthly migraine days [MMDs], and history of chronic migraine [CM]) reported in the phase II/III trial for rimegepant (NCT03732638). Four efficacy outcomes were compared between the two erenumab regimens (70 mg and 140 mg) and rimegepant, including changes in MMDs from baseline to month 1 and month 3, changes in Migraine-Specific Quality of Life Questionnaire role function – restrictive domain score from baseline to month 3, and change in disability from baseline to month 3. <b>Results: </b>Compared with rimegepant, erenumab 70 mg was associated with a statistically significant reduction in MMDs at month 3 (-0.90 [-1.76, -0.03]; p = 0.042) and erenumab 140 mg was associated with statistically significant reductions in MMDs at month 1 (-0.94 [-1.70, -0.19]; p = 0.014) and month 3 (-1.28 [-2.17, -0.40]; p = 0.005). The erenumab regimens also had numerical advantages over rimegepant for other efficacy outcomes. <b>Conclusion</b>: In the present study, we found that erenumab had a more favorable efficacy profile than rimegepant in reducing MMDs at month 1 and month 3 for migraine prevention. These results may help with decision-making in clinical practice and can be further validated in future clinical trials or real-world studies.
DOI: 10.48328/tudatalib-1345
title: Geochemical, petrophysical and petrographical dataset of fractured Variscan granites of the Cornubian Batholith, SW United Kingdom

description: Outcrop analogue studies are of high priority as they allow the interpretation of geophysical surveys, minimizing the exploration risk, reliable predictions of reservoir properties and drawing conclusions on expected discharge, before drilling in a cost-wise way. Detailed knowledge of the petrophysical properties and petrographical characteristics of potential reservoir rocks improve the interpretation of forthcoming borehole logging and of fluid flow in different zones. Built datasets yet comprise the development of the necessary input for static and dynamic reservoir model parametrization. In the framework of EU H2020 funded ‘MEET’ project (‘Multidisciplinary and multi-context demonstration of EGS exploration and Exploitation Techniques and potentials’, grant agreement no:792037) outcrop analogue samples from the Cornubian Batholith, located in SW United Kingdom, were taken from the onshore plutons namely Land’s End, Tregonning-Godolphin, Carnmenellis, Carn Brea, Carn Marth and St. Austell. 47 granitic samples were collected from 23 outcrops representative for fresh, weathered, hydrothermally altered, fractured and faulted granites. From the outcrop samples, 338 cores with different diameters were obtained and the measurements of grain density, bulk density, permeability, porosity, acoustic wave velocity, thermal conductivity, thermal diffusivity, magnetic susceptibility, uniaxial compressive strength, Poisson’s ratio, Young’s modulus, tensile strength, shear strength, cohesion, coefficient of friction and shear modulus were performed on oven-dried cores under ambient temperature and atmospheric pressure in the HydroThermikum laboratory of the Technical University of Darmstadt. Petrographical and geochemical characterization were done for 47 outcrop analogue samples and for the drill cuttings, taken between 3,980 and 5,275 m (measured depth) in UD1; the production well of United Downs Deep Geothermal Power Project, first commercial deep geothermal project of UK, through thin section analysis, X-ray diffraction (XRD) and X-ray fluorescence (XRF). This dataset presents the geochemical, petrophysical and petrographical properties of Early Permian aged fractured Variscan granite specifically not overprinted by any younger tectonic regime. It forms a basis to other publications, where the results of the aforementioned multiparameter rock characterization are discussed in detail and are used for stochastic regional resource assessment, respectively. It follows the same database structure as PetroPhysical Property Database (P³) of Bär et al. (2020). Each analyzed core is provided with a sample ID according to the naming convention within MEET project as ‘MEETCW001001001’ (Project name - region name - location number - sample number - core number).
DOI: 10.6084/m9.figshare.25070546
title: Supplementary material: Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers

description: <b>These are peer-reviewed data and glossary for the article '</b><b>Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><br>Full R code for implementing QBA of missing ECOG data and obtaining E-values for unknown confoundersGlossaryDevelopment of medicines in rare oncologic patient populations are growing, but well-powered randomized controlled trials are typically extremely challenging or unethical to conduct in such settings. External control arms using real-world data are increasingly used to supplement clinical trial evidence where no or little control arm data exists. The construction of an external control arm should always aim to match the population, treatment settings and outcome measurements of the corresponding treatment arm. Yet, external real-world data is typically fraught with limitations including missing data, measurement error and the potential for unmeasured confounding given a nonrandomized comparison. Quantitative bias analysis (QBA) comprises a collection of approaches for modelling the magnitude of systematic errors in data which cannot be addressed with conventional statistical adjustment. Their applications can range from simple deterministic equations to complex hierarchical models. QBA applied to external control arm represent an opportunity for evaluating the validity of the corresponding comparative efficacy estimates. We provide a brief overview of available QBA approaches and explore their application in practice. Using a motivating example of a comparison between pralsetinib single-arm trial data versus pembrolizumab alone or combined with chemotherapy real-world data for RET fusion-positive advanced non-small cell lung cancer (aNSCLC) patients (1–2% among all NSCLC), we illustrate how QBA can be applied to external control arms. We illustrate how QBA is used to ascertain robustness of results despite a large proportion of missing data on baseline ECOG performance status and suspicion of unknown confounding. The robustness of findings is illustrated by showing that no meaningful change to the comparative effect was observed across several ‘tipping-point’ scenario analyses, and by showing that suspicion of unknown confounding was ruled out by use of E-values. Full R code is also provided.
DOI: 10.6084/m9.figshare.25070546.v1
title: Supplementary material: Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers

description: <b>These are peer-reviewed data and glossary for the article '</b><b>Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><br>Full R code for implementing QBA of missing ECOG data and obtaining E-values for unknown confoundersGlossaryDevelopment of medicines in rare oncologic patient populations are growing, but well-powered randomized controlled trials are typically extremely challenging or unethical to conduct in such settings. External control arms using real-world data are increasingly used to supplement clinical trial evidence where no or little control arm data exists. The construction of an external control arm should always aim to match the population, treatment settings and outcome measurements of the corresponding treatment arm. Yet, external real-world data is typically fraught with limitations including missing data, measurement error and the potential for unmeasured confounding given a nonrandomized comparison. Quantitative bias analysis (QBA) comprises a collection of approaches for modelling the magnitude of systematic errors in data which cannot be addressed with conventional statistical adjustment. Their applications can range from simple deterministic equations to complex hierarchical models. QBA applied to external control arm represent an opportunity for evaluating the validity of the corresponding comparative efficacy estimates. We provide a brief overview of available QBA approaches and explore their application in practice. Using a motivating example of a comparison between pralsetinib single-arm trial data versus pembrolizumab alone or combined with chemotherapy real-world data for RET fusion-positive advanced non-small cell lung cancer (aNSCLC) patients (1–2% among all NSCLC), we illustrate how QBA can be applied to external control arms. We illustrate how QBA is used to ascertain robustness of results despite a large proportion of missing data on baseline ECOG performance status and suspicion of unknown confounding. The robustness of findings is illustrated by showing that no meaningful change to the comparative effect was observed across several ‘tipping-point’ scenario analyses, and by showing that suspicion of unknown confounding was ruled out by use of E-values. Full R code is also provided.
DOI: 10.6084/m9.figshare.25070408
title: Appendix: Estimating utility values for non-alcoholic steatohepatitis health states: a discrete choice experiment

description: <b>These are peer-reviewed supplementary appendices and figures for the article '</b><b>Estimating utility values for non-alcoholic steatohepatitis health states: a discrete choice experiment</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><br><b>Appendix file 1:</b> General Public DCE Survey<b>Appendix file 2:</b> Sample DCE choice questions<b>Appendix File 3:</b> Estimated marginal utilities among NASH patients by fibrosis stage based on results from conditional logit model<b>Appendix File 4: </b>NASH Check scores and frequency of symptoms by NASH Fibrosis Stage<b>Appendix File 5:</b> Linear regression results exploring associations between background and clinical characteristics with EQ-5D utility values in the patient sample (n=154)<b>Background:</b> This study estimated utility values for non-alcoholic steatohepatitis (NASH). Previous studies have assumed that health-related quality of life does not vary between the early stages of NASH. <b>Materials & Methods: </b>Discrete choice experiment (DCE) surveys estimated the value of avoiding fibrosis progression. Patients also completed the EQ-5D-5L. Marginal rates of substitution estimated utility change associated with fibrosis progression. <b>Results:</b> DCE surveys were completed by the UK general public (n = 520) and patients with NASH (n = 154). The utility decline between fibrosis stages F1 and F4 decompensated was between -0.521 to -0.646 (depending on method). <b>Conclusion:</b> Three methods were used to estimate utilities for NASH, each one showed sensitivity to advancing fibrosis, including in the early stages, which is often considered asymptomatic.
DOI: 10.6084/m9.figshare.25070408.v1
title: Appendix: Estimating utility values for non-alcoholic steatohepatitis health states: a discrete choice experiment

description: <b>These are peer-reviewed supplementary appendices and figures for the article '</b><b>Estimating utility values for non-alcoholic steatohepatitis health states: a discrete choice experiment</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><br><b>Appendix file 1:</b> General Public DCE Survey<b>Appendix file 2:</b> Sample DCE choice questions<b>Appendix File 3:</b> Estimated marginal utilities among NASH patients by fibrosis stage based on results from conditional logit model<b>Appendix File 4: </b>NASH Check scores and frequency of symptoms by NASH Fibrosis Stage<b>Appendix File 5:</b> Linear regression results exploring associations between background and clinical characteristics with EQ-5D utility values in the patient sample (n=154)<b>Background:</b> This study estimated utility values for non-alcoholic steatohepatitis (NASH). Previous studies have assumed that health-related quality of life does not vary between the early stages of NASH. <b>Materials & Methods: </b>Discrete choice experiment (DCE) surveys estimated the value of avoiding fibrosis progression. Patients also completed the EQ-5D-5L. Marginal rates of substitution estimated utility change associated with fibrosis progression. <b>Results:</b> DCE surveys were completed by the UK general public (n = 520) and patients with NASH (n = 154). The utility decline between fibrosis stages F1 and F4 decompensated was between -0.521 to -0.646 (depending on method). <b>Conclusion:</b> Three methods were used to estimate utilities for NASH, each one showed sensitivity to advancing fibrosis, including in the early stages, which is often considered asymptomatic.
DOI: 10.24403/jp.1318910
title: Barthel, K.-J. & Pusch, J. : Die Botaniker des Kyffhäusergebietes. Ein Beitrag zur Geschichte der floristischen Erforschung Nord-Thüringens und Südwest-Sachsen-Anhalts. - Weissdorn-Verlag, Jena, 2005. / [rezensiert von] Gerhard Wagenitz